Vaccine Code Set Update Publication Date: July 27, 2023
The individual filenames included in this distribution contain the publication date (20230727)
Release Notes: This release includes updates for all vaccine codes and maps, but does not include codes for Vaccine Information Statements (VIS).
General Note regarding this release: Codes with “Last Update” dates after June 7, 2023, and before July 26, 2023, reflect the changes and additions in this release. This release includes the following code set updates:
1) Respiratory Syncytial Virus (RSV) Related Codes
- New RSV vaccine codes
- New RSV nirsevimab monoclonal antibody codes
2) Seasonal Influenza Vaccines
- New influenza vaccines for the 2023/2024 season
- Retired influenza vaccines for 2022/2023 season
3) Other Vaccine Code Set Updates
- New vaccine codes, retired codes, and CPT to CVX code mapping changes
Vaccine Code Set Updates - Details
1) Respiratory Syncytial Virus (RSV) Related Codes
General – All RSV codes: CDC’s IIS Data Code Set webpage includes a new downloadable table “Respiratory Syncytial Virus (RSV) Codes and Crosswalks”. This table includes both vaccine and monoclonal antibody codes that have been added to the vaccine code sets for Fall 2023. This can be found at IIS Data Code Sets | CDC
All RSV related CVX codes shown in the following sections are associated to the Vaccine Group “RSV”. Product table entries have been added for the new tradenames. In addition, new CPT codes have been added and mapped to the new CVX codes.
The following new RSV vaccine codes have been added for the Pfizer RSV Abryzvo vaccine product for ages 60 and older.
Note that in the prior release of June 8, 2023, vaccine codes were added for the GSK Arexvy product (CVX code 303) and for an unspecified RSV vaccine code (CVX code 304).
Guidance relating to RSV vaccines can be found at Home page for MMWR | MMWR (cdc.gov)
Respiratory Syncytial Virus (RSV) Vaccine Codes Fall 2023 (*) |
|---|
CVX Code | CVX Description (long) | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|
305 | Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free | Abrysvo | Pfizer Laboratories Div Pfizer Inc | PFR | 0069-0344-01
0069-0344-05
0069-0344-10 | 0069-0207-01 | VIAL, 0.5 mL, reconstituted | 90678 | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use |
|---|
- New RSV nirsevimab monoclonal antibody codes
On July 17, 2023, the Food and Drug Administration licensed Nirsevimab (Beyfortus), a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) in infants and young children. It is anticipated that the Advisory Committee on Immunization Practices (ACIP) will vote on potential recommendations for use of this product and its inclusion in the Vaccines for Children (VFC) program at the August 3rd ACIP meeting.
New codes have been added for the Sanofi nirsevimab (Beyfortus) mAb. They have been added in anticipation of potential recommendations. More information to support integration into VFC, as well as details around vaccine codes, Clinical Decision Support for Immunization (CDSi), and any data collection requirements will be published as they become available.
The new codes are listed in the table below. Please note that the BEYFORTUS nirsevimab monoclonal antibody codes are included in the vaccine code set in a manner similar to regular vaccines to enable reporting or other program data exchange in accordance with ACIP and CDC guidelines. While these are not true vaccines, they have not been identified as “non-vaccine” in the code set.
Respiratory Syncytial Virus (RSV) Monoclonal Antibody Codes Fall 2023 (*) |
|---|
CVX Code | CVX Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|
306 | Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months | BEYFORTUS | Sanofi Pasteur Inc. | PMC | 49281-575-15 | 49281-575-00 | SYRINGE, 0.5 mL | 90380 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use |
|---|
307 | Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1.0 mL, neonates and children to 24 months | BEYFORTUS | Sanofi Pasteur Inc. | PMC | 49281-574-15 | 49281-574-88 | SYRINGE, 1.0 mL | 90381 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use |
|---|
2) Seasonal Influenza Vaccines
- New influenza vaccines for the 2023/2024 season
The majority of the new seasonal influenza vaccines for the 2023/2024 season are included in this release. There are no new CVX codes. Below are the new vaccine codes that have been added thus far. We anticipate new codes still to come for Flumist. There will be a follow-up code set release in August with any remaining new vaccine codes.
The IIS Data Code Set webpage includes a downloadable table “Seasonal Influenza Codes and Crosswalk”. This can be found at IIS Data Code Sets | CDC
Table: New Seasonal Influenza Vaccine Codes 2023/2024
CVX Code | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation |
|---|
149 | influenza, live, intranasal, quadrivalent | FluMist Quadrivalent | MedImmune, LLC | MED | NA | NA | NA |
|---|
150 | Influenza, injectable, quadrivalent, preservative free | Afluria Quadrivalent | Seqirus PTY Lth. | SEQ | 33332-0323-03 | 33332-0323-04 | SYRINGE, 0.5 mL |
|---|
150 | influenza, injectable, quadrivalent, preservative free | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | SKB | 58160-0909-52 | 58160-0909-41 | SYRINGE, 0.5 mL |
|---|
150 | influenza, injectable, quadrivalent, preservative free | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | IDB | 19515-0814-52 | 19515-0814-41 | SYRINGE, 0.5 mL |
|---|
150 | influenza, injectable, quadrivalent, preservative free | Fluzone Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0423-50 | 49281-0423-88 | SYRINGE, 0.5 mL |
|---|
158 | influenza, injectable, quadrivalent, contains preservative | Afluria Quadrivalent | Seqirus PTY Lth. | SEQ | 33332-0423-10 | 33332-0423-11 | VIAL, 5 mL, MULTI-DOSE |
|---|
158 | influenza, injectable, quadrivalent | Fluzone Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0639-15 | 49281-0639-78 | VIAL, 5 mL, MULTI-DOSE |
|---|
171 | Influenza, injectable, MDCK, preservative free, quadrivalent | Flucelvax Quadrivalent | Seqirus Inc. | SEQ | 70461-0323-03 | 70461-0323-04 | SYRINGE, 0.5 mL |
|---|
185 | influenza, recombinant, quadrivalent, injectable, preservative free | Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0723-10 | 49281-0723-88 | SYRINGE, 0.5 mL |
|---|
186 | Influenza, injectable, MDCK, quadrivalent, preservative | Flucelvax Quadrivalent | Seqirus Inc. | SEQ | 70461-0423-10 | 70461-0423-11 | VIAL, 5 mL, MULTI-DOSE |
|---|
197 | influenza, high-dose, quadrivalent | Fluzone High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0123-65 | 49281-0123-88 | SYRINGE, 0.7 mL |
|---|
205 | Influenza vaccine, quadrivalent, adjuvanted | FLUAD QUADRIVALENT | Seqirus, Inc. | SEQ | 70461-0123-03 | 70461-0123-04 | SYRINGE, 0.5 ml |
|---|
- Retired influenza vaccine codes for 2022/2023 season
The following influenza vaccine NDC pairs have been retired in this release.
|
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 |
|---|
FLUAD QUADRIVALENT | Seqirus, Inc. | 70461-0122-03 | 70461-0122-04 |
|---|
Flucelvax Quadrivalent | Seqirus Inc. | 70461-0322-03 | 70461-0322-04 |
|---|
Flucelvax Quadrivalent | Seqirus Inc. | 70461-0422-10 | 70461-0422-11 |
|---|
Afluria Quadrivalent | Seqirus PTY Lth. | 33332-0422-10 | 33332-0422-11 |
|---|
Afluria Quadrivalent | Seqirus PTY Lth. | 33332-0322-03 | 33332-0322-04 |
|---|
FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 58160-0890-52 | 58160-0890-41 |
|---|
Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 19515-0808-52 | 19515-0808-41 |
|---|
Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0722-10 | 49281-0722-88 |
|---|
3) Other Vaccine Code Set Updates
New NDCs for TENIVAC have been added for relabeler A-S Medication Solutions. The product is manufactured by Sanofi and mapped to the Sanofi MVX code.
|
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | CVX Code | CVX Description | MVX Code |
|---|
TENIVAC | A-S Medication Solutions | 50090-2062-00 | 50090-2062-01 | 113 | th (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | PMC |
|---|
The following NDCs have been retired and end dates have been added to the records in this release. Note that the RECOMBIVAX units of use associated to the retired NDCs have not been retired and continue to be associated to other units of sale.
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 |
|---|
Janssen COVID-19 Vaccine | Janssen Products, LP | 59676-0580-15 | 59676-0580-05 |
|---|
VARIVAX | Merck Sharp & Dohme LLC | 00006-4826-00 | 00006-4826-01 |
|---|
RECOMBIVAX HB | Merck Sharp & Dohme LLC | 00006-4093-09 | Not Retired |
|---|
RECOMBIVAX HB | Merck Sharp & Dohme LLC | 00006-4094-09 | Not Retired |
|---|
- CPT to CVX Code Mapping Changes
CDC maps CPT codes to CVX codes, not directly to the NDCs or product codes. Editorial policy generally only allows a single CPT code to be mapped to one CVX Code. Occasionally this policy results in a situation when there is no CPT mapped to a CVX code. The following changes have been made to the CPT to CVX maps:
- CPT code 90734, “Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use”. Note that the description of this CPT code was updated in 2020 to add the second formulation to the description.
- Originally mapped to CVX code 114 “meningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4P)”. This CVX code is associated to the product and NDCs for Menactra.
- This release adds an additional (2nd) map to CVX code 136 “meningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O)”. This CVX code is associated to the product and NDCs for Menveo.
